Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cypherpunk Technologies Inc. filings document the issuer's transition from Leap Therapeutics, its Zcash-focused digital asset treasury activity, and formal public-company reporting after the name change. Current reports cover financial results, ZEC purchases, material agreements, equity offering arrangements, capital-structure disclosures, and Nasdaq listing-compliance notices.
Proxy materials cover annual meeting voting and board governance for the renamed company. The filing record also preserves disclosure categories tied to the company's prior oncology identity, including corporate status, risk factors, financing arrangements, and governance matters connected to its continuing subsidiary-based therapeutic research operations.
Leap Therapeutics, Inc. received an additional 180-day grace period from Nasdaq, until March 9, 2026, to regain compliance with the Nasdaq Capital Market’s $1.00 minimum bid price requirement for its common stock. The extension was granted because the company met all other initial listing standards, including the market value of publicly held shares.
During this second compliance period, Leap Therapeutics could still be delisted if it fails to satisfy other Nasdaq listing rules. The company plans to monitor its share price and may consider a reverse stock split to restore compliance, but there is no assurance it will succeed or avoid eventual delisting.
Schedule 13G/A disclosure for Leap Therapeutics, Inc. (LPTX) This filing is a joint Schedule 13G/A by Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju reporting that, as of June 30, 2025, each Reporting Person beneficially owns 0 shares (0.0%) of Leap Therapeutics common stock (CUSIP 52187K200). The Reporting Persons state they are not a "group" and provide a Palo Alto business address for the filer. The filing incorporates a prior Joint Filing Statement by reference and is signed by Srinivas Akkaraju on behalf of the entities on August 14, 2025. The statement certifies the securities were not acquired to influence control of the issuer.
Leap Therapeutics, Inc. (LPTX) filed a Form 8-K reporting an item related to Results of Operations and Financial Condition and furnished a press release as an exhibit. The filing identifies Item 9.01 (Financial Statements and Exhibits) and lists Exhibit 99.1 as a press release dated August 14, 2025. The disclosure is signed by Douglas E. Onsi, Chief Executive Officer and President. The document does not include financial statements, earnings figures, transaction details, or other substantive operational data within the provided text.
Leap Therapeutics reported a difficult quarter marked by clinical progress on its lead asset but acute financial stress. Updated DeFianCe Part B data showed sirexatamab (DKN-01) produced a statistically significant benefit on overall response rate and progression-free survival in colorectal cancer patients with high DKK1, no prior anti‑VEGF therapy, or liver metastasis, with final study results being prepared for conference presentation.
Financially, the company had $18.13 million in cash and cash equivalents and $20.04 million total assets as of June 30, 2025, and reported a $32.08 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $499.45 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern, implemented a workforce reduction of approximately 75% and recorded $4.53 million of restructuring charges, and engaged Raymond James to explore strategic alternatives.